GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This is a 107-week open-label, multi-center long-term extension study from GALLANT studies
2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in
patients with type 2 diabetes during up to 104 weeks of treatment. The total duration,
including treatment and follow-up, is 107 weeks.